RET and non-small cell lung carcinoma: Following the review of updated results from an additional 172 patients and 18 months of additional follow-up to assess durability of response, the FDA subsequently granted regular approval to selpercatinib (21 September 2022) for adult patients with locally advanced or metastatic NSCLC with a RET fusion, as detected by an FDA-approved test.